Portal de Periódicos da CAPES

Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study

2021; Taylor & Francis; Volume: 10; Issue: 1 Linguagem: Inglês

10.1080/22221751.2021.1969291

2222-1751

Xiaoning Li, Yong Huang, Wen Wang, Qinlong Jing, Chunhuan Zhang, Pengzhe Qin, Wei‐jie Guan, Lin Gan, Yilan Li, Wenhui Liu, Hang Dong, Yutian Miao, Shujun Fan, Zhoubin Zhang, Dingmei Zhang, Nanshan Zhong,

COVID-19 epidemiological studies

The effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant, which has been associated with greater transmissibility and virulence, remains unclear. We conducted a test-negative case–control study to explore the vaccine effectiveness (VE) in real-world settings. We recruited participants aged 18–59 years who consisted of SARS-CoV-2 test-positive cases (n = 74) and test-negative controls (n = 292) during the outbreak of the Delta variant in May 2021 in Guangzhou city, China. Vaccination status was compared to estimate The VE of SARS-CoV-2 inactivated vaccines. A single dose of inactivated SARS-CoV-2 vaccine yielded the VE of only 13.8%. After adjusting for age and sex, the overall VE for two-dose vaccination was 59.0% (95% confidence interval: 16.0% to 81.6%) against coronavirus disease 2019 (COVID-19) and 70.2% (95% confidence interval: 29.6–89.3%) against moderate COVID-19 and 100% against severe COVID-19 which might be overestimated due to the small sample size. The VE of two-dose vaccination against COVID-19 reached 72.5% among participants aged 40–59 years, and was higher in females than in males against COVID-19 and moderate diseases. While single dose vaccination was not sufficiently protective, the two-dose dosing scheme of the inactivated vaccines was effective against the Delta variant infection in real-world settings, with the estimated efficacy exceeding the World Health Organization minimal threshold of 50%.